Disc Medicine Files Q1 2025 10-Q, Details Mabwell & Roche Deals
Ticker: IRON · Form: 10-Q · Filed: May 7, 2025 · CIK: 1816736
| Field | Detail |
|---|---|
| Company | Disc Medicine, Inc. (IRON) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, license-agreement, financing
TL;DR
**Disc Medicine Q1 10-Q out: Mabwell & Roche deals detailed, $0M revenue but cash burn continues.**
AI Summary
Disc Medicine, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, including details on its license agreements with Mabwell Therapeutics Inc. and Roche. The filing also mentions a January 2025 underwritten offering.
Why It Matters
This filing provides investors with an update on Disc Medicine's financial health and strategic partnerships, crucial for understanding the company's progress in drug development.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Disc Medicine faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- 20250331 — Reporting Period End Date (The end of the first fiscal quarter for 2025.)
- 20250507 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Disc Medicine, Inc. (company) — Filer of the 10-Q
- Mabwell Therapeutics Inc. (company) — Party to a license agreement
- Roche (company) — Party to a license agreement
- Jean Franchi (person) — Mentioned in relation to March 31, 2025
- January TwoThousandAndTwentyFiveUnderwrittenOffering (dollar_amount) — A financial event in January 2025
FAQ
What is the nature of the license agreement with Mabwell Therapeutics Inc.?
The filing indicates a license agreement with Mabwell Therapeutics Inc. for the period of January 1, 2025, to March 31, 2025.
When was the license agreement with Roche entered into?
The license agreement with Roche was entered into on December 29, 2022.
What significant financial event occurred in January 2025?
An underwritten offering, referred to as 'JanuaryTwoThousandAndTwentyFiveUnderwrittenOffering', took place in January 2025.
What is the company's former name?
The company was formerly known as Gemini Therapeutics, Inc. /DE and FS Development Corp.
What is the company's primary industry classification?
Disc Medicine, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 by Jean Franchi regarding Disc Medicine, Inc. (IRON).